540 related articles for article (PubMed ID: 30352626)
1. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.
Tarhini A; Lin Y; Lin H; Rahman Z; Vallabhaneni P; Mendiratta P; Pingpank JF; Holtzman MP; Yusko EC; Rytlewski JA; Rao UNM; Ferris RL; Kirkwood JM
J Immunother Cancer; 2018 Oct; 6(1):112. PubMed ID: 30352626
[TBL] [Abstract][Full Text] [Related]
2. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
[TBL] [Abstract][Full Text] [Related]
3. CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma.
Khunger A; Piazza E; Warren S; Smith TH; Ren X; White A; Elliott N; Cesano A; Beechem JM; Kirkwood JM; Tarhini AA
PLoS One; 2021; 16(1):e0245287. PubMed ID: 33428680
[TBL] [Abstract][Full Text] [Related]
4. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
Retseck J; Nasr A; Lin Y; Lin H; Mendiratta P; Butterfield LH; Tarhini AA
J Transl Med; 2018 Jul; 16(1):184. PubMed ID: 29973204
[TBL] [Abstract][Full Text] [Related]
5. Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma.
Mangana J; Dimitriou F; Braun R; Ludwig S; Dummer R; Barysch MJ
Melanoma Res; 2019 Dec; 29(6):648-654. PubMed ID: 30870270
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma.
Najjar YG; McCurry D; Lin H; Lin Y; Zang Y; Davar D; Karunamurthy A; Drabick JJ; Neves RI; Butterfield LH; Ernstoff MS; Puzanov I; Skitzki JJ; Bordeaux J; Summit IB; Bender JO; Kim JY; Chen B; Sarikonda G; Pahuja A; Tsau J; Alfonso Z; Laing C; Pingpank JF; Holtzman MP; Sander C; Rose A; Zarour HM; Kirkwood JM; Tarhini AA
Clin Cancer Res; 2021 Aug; 27(15):4195-4204. PubMed ID: 33753453
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.
Reuss JE; Anagnostou V; Cottrell TR; Smith KN; Verde F; Zahurak M; Lanis M; Murray JC; Chan HY; McCarthy C; Wang D; White JR; Yang S; Battafarano R; Broderick S; Bush E; Brock M; Ha J; Jones D; Merghoub T; Taube J; Velculescu VE; Rosner G; Illei P; Pardoll DM; Topalian S; Naidoo J; Levy B; Hellmann M; Brahmer JR; Chaft JE; Forde PM
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929052
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.
Patel SP; Kim DW; Bassett RL; Cain S; Washington E; Hwu WJ; Kim KB; Papadopoulos NE; Homsi J; Hwu P; Bedikian AY
Cancer Immunol Immunother; 2017 Oct; 66(10):1359-1366. PubMed ID: 28612140
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma.
Salama AKS; Palta M; Rushing CN; Selim MA; Linney KN; Czito BG; Yoo DS; Hanks BA; Beasley GM; Mosca PJ; Dumbauld C; Steadman KN; Yi JS; Weinhold KJ; Tyler DS; Lee WT; Brizel DM
Clin Cancer Res; 2021 Mar; 27(5):1287-1295. PubMed ID: 33172894
[TBL] [Abstract][Full Text] [Related]
13. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
14. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
Tarhini AA; Lee SJ; Hodi FS; Rao UNM; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
J Clin Oncol; 2020 Feb; 38(6):567-575. PubMed ID: 31880964
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
16. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma.
Tarhini AA; Lee SJ; Li X; Rao UNM; Nagarajan A; Albertini MR; Mitchell JW; Wong SJ; Taylor MA; Laudi N; Truong PV; Conry RM; Kirkwood JM
Clin Cancer Res; 2019 Jan; 25(2):524-532. PubMed ID: 30420448
[TBL] [Abstract][Full Text] [Related]
17. Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.
Jamal R; Lapointe R; Cocolakis E; Thébault P; Kazemi S; Friedmann JE; Dionne J; Cailhier JF; Bélanger K; Ayoub JP; Le H; Lambert C; El-Hajjar J; van Kempen LC; Spatz A; Miller WH
J Immunother Cancer; 2017 Nov; 5(1):83. PubMed ID: 29157311
[TBL] [Abstract][Full Text] [Related]
18. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
19. Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.
Bjoern J; Lyngaa R; Andersen R; Hölmich LR; Hadrup SR; Donia M; Svane IM
Oncotarget; 2017 Apr; 8(16):27062-27074. PubMed ID: 28423678
[TBL] [Abstract][Full Text] [Related]
20. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab.
Tobin RP; Jordan KR; Robinson WA; Davis D; Borges VF; Gonzalez R; Lewis KD; McCarter MD
Int Immunopharmacol; 2018 Oct; 63():282-291. PubMed ID: 30121453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
